Further evaluation of the effects of miR-548ag inhibitor in improving the body’s glucose tolerance and insulin sensitivity will provide a theoretical basis for miR-548ag to become a candidate drug target for the clinical treatment of obesity and related metabolic diseases. This evidence concerns the gene INS and obesity disorder.